Prospective study on the incidence and management of drug-induced skin reactions in a tertiary care hospital
Background: Drug-induced skin reactions (DISRs) are common adverse drug reactions observed in hospitalized patients. They range from mild conditions such as rashes to severe and potentially life-threatening disorders like Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN). Despite their clinical significance, data on the incidence, clinical patterns, and management of DISRs in India remains limited.
Objective: To evaluate the incidence, clinical spectrum, suspected drug classes, latency period, and outcomes of drug-induced skin reactions in patients attending a tertiary care hospital over a period of one year.
Methods: This prospective observational study was conducted in the Dermatology and General Medicine departments of a tertiary care hospital. A total of 100 patients with suspected DISRs were enrolled based on specific inclusion and exclusion criteria. Data collected included demographic details, drug history, clinical examination, and diagnostic tests. Management involved immediate withdrawal of suspected drugs, symptomatic treatment, and, when necessary, intensive care for severe reactions. Follow-up was carried out until complete resolution or as required.
Results: The study included 100 patients, with a mean age of 38.6 ± 14.7 years. Maculopapular rashes (40%) were the most common clinical manifestation, followed by urticaria (25%) and fixed drug eruptions (15%). Antibiotics (35%) and NSAIDs (30%) were the most frequently implicated drug classes. The latency period for skin reactions ranged from less than 24 hours to more than a week, with 90% of patients achieving complete resolution. Severe reactions like SJS/TEN were observed in 6% of cases, leading to 2 deaths.
Conclusion: This study highlights the significant incidence of drug-induced skin reactions in a tertiary care setting, with antibiotics, NSAIDs, and anticonvulsants being the most common culprits. Early recognition and prompt cessation of the offending drug, along with appropriate symptomatic management, are crucial for positive patient outcomes. Enhanced pharmacovigilance and awareness among healthcare providers are essential for the effective management of DISRs. Further research into genetic factors contributing to these reactions is warranted.